Press release
Launch of Moolchand Swine Flu (H1N1) Screening Centre
Moolchand Medcity, in its efforts to assist the government in curtailing the spread of swine flu, has launched Moolchand Swine Flu (H1N1) Screening Centre at our Medcity campus (Lajpat Nagar).Our Centre offers H1N1 screening test, advices treatment and domiciliary quarantine for patients with mild to moderate symptoms and has an isolation ward facility for seriously ill patients.
Dr. Ellora Nanda OPD Coordinator and Nodal Officer-Moolchand Swine Flu (H1N1) Screening Centre, Moolchand Medcity said, “People with symptoms like fever, cough, sore throat, body aches, headache, chills, fatigue, diarrhea and vomiting in some cases for more than 3 days may be at risk and should immediately get themselves tested.”
Moolchand is one of the first private hospitals in Delhi to be authorized by the Department of Health and Family Welfare, Government of India as a screening cum isolation facility unit for managing swine flu (H1N1) patients. In conformance with this approval, the Moolchand Swine Flu (H1N1) Screening Centre is following all clinical management protocols and infection control guidelines as per WHO and Directorate General of Health Services, Government of India.
To minimize cross infection, screenings at our Centre are done by appointments only (9 am to 5:30 pm). You may call Front Office Assistance (H1N1) at +91 98180 39901 to fix an appointment.
About Moolchand
As one of India’s foremost names in healthcare, Moolchand has been setting standards for the past half century. Located in the heart of the capital, the plans are to develop Moolchand Medcity as Asia’s largest single site multispecialty hospital complex (6 specialties, 1000+ beds). We aspire to be your lifelong healthcare partner by delivering your healthcare wishlist: superb physicians, cutting-edge technology, compassionate care, integrity and affordable excellence. Moolchand is the first multispecialty hospital in North India to receive the National Accreditation Board for Hospital and Healthcare Providers (NABH) accreditation and ISO certification (9001:2000, 27001 and Platinum).
Moolchand Medcity
Lajpat Nagar III
New Delhi-110 024
M 91 99589 97291
E info@moolchandhealthcare.com
F 91 11 4200 0300
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Launch of Moolchand Swine Flu (H1N1) Screening Centre here
News-ID: 104417 • Views: …
More Releases from Moolchand Medcity
Moolchand offers International Post Graduate Program in Emergency Medicine
Moolchand Medcity, New Delhi, August 13, 2010: Moolchand Medcity has partnered with The Ronald Reagan Institute of Emergency Medicine (RRIEM) at the George Washington University, USA to offer 3-year Post Graduate Program in Emergency Medicine. It is amongst the most prestigious international post graduate training programs available in emergency medicine in India.
Mr. Vibhu Talwar, Chief Operating Officer, Moolchand Medcity said that “It is a 3-year Post…
High Risk Renal Cell Carcinoma Surgery Successfully Performed at Moolchand
Moolchand Medcity, New Delhi, May 30, 2009 - A rare surgery on a 23 year old Nigerian girl Akani Chimenem Paul suffering from kidney tumour (Renal Cell Carcinoma) was successfully conducted at Moolchand Medcity. A team of eminent super-specialists from Moolchand took up the challenge and performed the surgery successfully by removing the 4 kg tumour with minimal blood loss. The team of Moolchand physicians who operated this…
More Releases for H1N1
Rise In R&D Investments Drives The H1N1 Vaccine Market: A Significant Driver Pro …
The H1N1 Vaccine Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the H1N1 Vaccine Market Size and Projected Growth Rate?
The market size of the H1N1 vaccine has significantly expanded in the recent past. Its growth is projected to rise from $3.33 billion in…
H1N1 (Swine Influenza) - Drug Pipeline Landscape, 2022
Global Insight Services have recently published a report on H1N1 (Swine Influenza) Pipeline landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
The H1N1 flu (swine flu) is primarily caused by the H1N1 strain of the flu (influenza) virus. It is a communicable viral illness causing upper and lower respiratory tract infections.
Swine flu H1N1 infects the cells that line…
H1N1 Vaccines Market Opportunity Analysis, 2018 – 2026
H1N1 influenza virus causes viral disease, commonly known as swine flu, which mostly affects the respiratory system. Swine flu is characterized by infection from H1N1 strain. Symptoms of H1N1 flu are fever, cough, sore throat, runny or stuffy nose, watery and red eyes, body aches, headache, fatigue, and diarrhea. H1N1 spreads through contact with contaminated air or geographical locations infected with virus. H1N1 infection may worsen other chronic respiratory conditions…
H1N1 Vaccination Market - Global Industry Analysis 2023
H1N1 influenza virus or swine H1N1 virus is a causative agent of infectious disease caused in human beings known as H1N1 or commonly referred as swine flu. The H1N1 virus mainly affects the respiratory system including nose, lungs and throat of the infected person. In addition to human, H1N1 virus affects various species such as birds, swine, horses etc.
The H1N1 influenza virus caused a worldwide pandemic in the recent…
H1N1 Vaccines Market Rugged Expansion Foreseen by 2021
The H1N1 Vaccines Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
A vaccine is a biological preparation consisting of an agent that closely resembles a disease-causing microorganism and is made from weakened or killed forms of the microbe, its toxins or one…
Europe H1N1 Vaccines Market 2017
Latest market study on " Europe H1N1 Vaccines Market Report: 2017 " available with Single User Europe USD 3900 at OrbisResearch.com
The H1N1 Vaccines Market report covers the present scenario and the growth prospects of the Europe H1N1 Vaccines market for 2017-2022 The report covers the market landscape and its growth prospects over the coming years. To calculate the market size , market share, market growth, market analysis , market…
